MP
STML

Mangrove Partners’s Stemline Therapeutics, Inc. STML Stock Holding History

Mangrove Partners’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-636,513
Closed -$8.18M – 95
2019
Q1 		$8.18M Buy
+636,513
New +$7.2M 1.09% 23

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Mangrove Partners's STML Position: Q2 2019 in Review

Mangrove Partners sold out of Stemline Therapeutics, Inc. (STML) in Q2 2019, closing a stake of 636,513 shares — an estimated $8.18M sold.

Mangrove Partners first reported a position in STML in Q1 2019 and held it in 1 quarter. The position peaked at $8.18M in Q1 2019. 96 funds tracked by Wall St. Rank hold STML as of Q2 2019.

  • Mangrove Partners reported no remaining Stemline Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Mangrove Partners sold 636,513 Stemline Therapeutics, Inc. shares in Q2 2019, an estimated $8.18M.
  • Mangrove Partners first reported a position in Stemline Therapeutics, Inc. in Q1 2019 and held it in 1 quarter.
  • Mangrove Partners's Stemline Therapeutics, Inc. position peaked at $8.18M in Q1 2019.
  • 96 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2019.

Based on Mangrove Partners's 13F filing for Q2 2019, filed 14 Aug 2019.